Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The hemophilia treatment market in Japan is expected to witness steady growth during the forecast period, with a projected CAGR of 6.16% from 2025 to 2033. By the end of this period, the market is ...

Sandi Tenza shares her journey with her son Sanda, diagnosed with haemophilia A, and the urgent need for awareness and ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

In this cohort of individuals with hemophilia, the physical activity levels and step count did not significantly differ between severity phenotypes. Evidence Rating Level: 1 (Excellent) Hemophilia is ...